The drug has demonstrated an almost complete reduction of liver fat by approximately 75% and helps shed 20% of body weight, both significant results for individuals grappling with fatty liver and obesity
Wegovy has been on the UK market since 2022, which means there are now several years of real-world safety data on top of the trial results
All of the animal studies were conducted on diabetic rats, including three studies on type 1 diabetic rats and six studies on type 2 [17,18,19,20,21,22,23,24,25]
According to drugs.com, semaglutide has been used to treat type II diabetes since receiving FDA approval under the brand name Ozempic in 2017 as a longer-lasting alternative to the daily self-injection, liraglutide (Victoza and other brand names).[1] After practices reported significant weight loss trends among users of semaglutide for diabetes, semaglutide was sent into FDA trials to be approved for weight loss therapy